drugset / Trial / NCT00882258
Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
RandomizedParallel-groupDouble-blindTreatment
Summary
Two (2) dose levels of Proellex or placebo will be administered once-daily for up to 91 days. Following screening and a pre-treatment endometrial biopsy, subjects will be followed monthly for the three month treatment phase.
Timeline
- Start
- 2006-03
- Primary completion
- 2007-03
- Completion
- 2007-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telapristone Acetate | Other / unclassified | 12.5 mg | Oral |
| Subject | Telapristone Acetate | Other / unclassified | 25 mg | Oral |